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The role of cigarette smoking and its interaction with cyclooxygenase-2 in acute
ulcerative colitis in mice
ESL Liu, VY Shin, YN Ye & CH Cho. Departments of Pharmacology, Faculty of Medicine, The University of Hong Kong,
Hong Kong, China.
Introduction: Epidemiological studies show that smokers are more likely to have Crohn’s disease but are less
susceptible to ulcerative colitis. Our previous study indicated that passive cigarette smoking exacerbated the Crohn’s
disease induced by 2,4,6-trinitrobenzene sulfonic acid in rats. However, no direct evidence had been found regard-
ing the protective effect of cigarette smoking on ulcerative colitis. Besides, cyclooxygenase-2 (COX-2) is strongly
associated with inflammatory bowel disease for its inhibition could either potentiate or attenuate colitis. The aim of
the present study is to evaluate the role of cigarette smoking on ulcerative colitis induced by dextran sulfate sodium
(DSS) in mice and to determine whether COX-2 takes part in the inflammatory process in this model.
Methods: Acute ulcerative colitis was induced in balb/c mice by giving 5% DSS in drinking water for 7 days. The
mice were simultaneously exposed to passive 0% or 2% cigarette smoke (CS) once daily for the same period of
time. Colonic tissues were assessed for the inflammatory parameters and COX-2 expression in these animals.
Results: DSS in drinking water given for 7 days increased colon weight when compared with the control. Histol-
ogy findings revealed that there were infiltration of inflammatory cells and loss of glands in the colonic mucosa. An
increase in myeloperoxidase (MPO) activity, a marker for neutrophils infiltration, was also observed. Both
immmunohistochemistry and Western immunoblotting indicated that COX-2 was induced in the colonic tissues
with ulcerative colitis. It was accompanied with an induction of the cellular proliferation. On the other hand, pas-
sive CS exposure neither affected the degree of inflammation nor the MPO activity in these animals. However, both
COX-2 protein expression and cellular proliferation was increased in colonic tissue in mice with CS exposure alone
and synergistically induced in mice when combined with DSS.
Conclusion: Passive cigarette smoking did not influence the severity of acute colonic inflammation induced
by DSS though it further provoked COX-2 expression and cellular proliferation in colitis animals. Furthermore,
COX-2 was induced by CS exposure alone but did not accompany with colitis formation. All these findings
indicated that COX-2 was not directly involved in the initiation of inflammation in this acute ulcerative
colitis model. However, whether the induction of cigarette smoke on proliferation exerts beneficial effect on
ulcerative colitis is undefined and requires further study.
Randomised controlled study of rabeprazole, levofloxacin and rifabutin triple
therapy versus quadruple therapy as second-line treatment of Helicobacter pylori
infection
W.M. Wong, Q. Gu, S.K. Lam, F.M.Y. Fung, K.C. Lai, W.H.C. Hu, Y.K. Yee, C.K. Chan, H.H.X. Xia, M.F. Yuen, B.C.Y. Wong
Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong
Background and aims: To test the efficacy of rabeprazole, levofloxacin and rifabutin triple therapy versus
rabeprazole-based quadruple therapy for the treatment of Helicobacter pylori (H. pylori) infection after failure of
one or more courses of H. pylori eradication therapy.
Methods: One hundred and nine patients who failed previous H. pylori eradication were randomised to receive 1)
rabeprazole 20mg twice daily, rifabutin 300mg and levofloxacin 500mg once daily for 7 days (RRL) or 2) rabeprazole
20mg twice daily, metronidazole 400mg thrice daily, bismuth subcitrate 120mg and tetracycline 500mg four times
daily for 7 days (quadruple). Endoscopy with biopsy for CLO test, histology and culture was performed before
treatment. Post-treatment H. pylori status was determined by 13C-urea breath test. Metronidazole, clarithromycin
and amoxycillin resistance was defined as MIC of >8 ug/ml, >2 ug/ml and >2 ug/ml respectively.
Results: The clarithromycin resistance rate (79% versus 21%, P<0.001) and metronidazole resistance rate
(89% versus 40%, P<0.001) was significantly higher in patients who have taken these antibiotics in their
previous H. pylori treatment compared to those who have not. Intention-to-treat and per protocol H. pylori
eradication rate were 91% / 91% for the RRL group and 91% / 92% for the quadruple group. For patients
with double resistance to metronidazole and clarithromycin, the eradication rates were 85% (17/20) in the
RRL group and 87% (13/15) in the quadruple group. Compliance was greater than 95% for both regimens.
Conclusion: Rabeprazole, levofloxacin and rifabutin based triple therapy and rabeprazole-based quadruple therapy
were equally effective as a second-line treatment of H. pylori infection.
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